Sunshine Biopharma Raises $6M in Public Offering for Drug Pipeline
Sunshine Biopharma (SBFM) closes $6M public offering to fund generic drug expansion and novel mRNA and antiviral programs. Learn more about the company's pipeline.
This funding is crucial for Sunshine Biopharma as it balances commercializing generic drugs in Canada with advancing high-potential mRNA and antiviral therapies. Success could bring new liver cancer treatments and COVID-fighting drugs to market, impacting patients and investors alike.
